Skip to content

Author

P. Vadagam

We have 1 of 22 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world clinical outcomes among patients with EGFR-mutated (Ex19del/L858R) metastatic NSCLC treated at City of Hope with osimertinib monotherapy by TP53 alteration status.

703 Background: Epidermal growth factor receptor mutations (EGFRm) occur in ~15% of non-small cell lung cancer (NSCLC) cases, with exon 19 deletions (Ex19del) and exon 21 L858R substitutions (L858R) comprising 85-90%. Osimertinib (Osi) monotherapy (mono) is one of the first-line (1L) treatment options, while mo...

S. Gruber, P. Vadagam, L. Morrison et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.